№ files_lp_4_process_3_133384
File format: docx
Character count: 1386
File size: 107 KB
The document presents a detailed table showing the activities of various D201 mutant codons and their corresponding amino acids in different strains.
Year:
2021
Region / city:
N/A
Topic:
Mutant codon activities
Document type:
Research table
Organization / institution:
N/A
Author:
N/A
Target audience:
Researchers in genetics and molecular biology
Effective period:
N/A
Approval date:
N/A
Date of amendments:
N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Region / city:
Not specified
Topic:
Cancer research, EGFR mutations
Document type:
Research figure
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Researchers, oncologists
Effective period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2022–2023
Region / City:
Bavikere, Shivamogga, Karnataka, India
Crop:
Blackgram (Vigna mungo L.)
Type of Document:
Research article
Institution:
Agricultural and Horticultural Research Station (AHRS)
Experimental Material:
90 F4M3 lines from PU31 × Rashmi cross, 30 selected F5M4 lines
Methods:
Field experiment, augmented and RCBD designs, gamma irradiation treatment (20 Kr)
Target Trait:
Yellow Vein Mosaic Virus (YVMV) resistance
Key Measurements:
Seed yield, disease incidence, disease index, PCV, GCV, heritability, genetic advance
Significant Lines:
BLM 9, BLM 20, BLM 29, BLM 44, BLM 51, BLM 58 (first season); BLM 30, BLM 51 (second season)
Document type:
Supplementary material
Study focus:
Construction and validation of kduD gene mutants
Methodology:
CRISPR/Cas9 system and transposon mutagenesis
Organism:
Escherichia coli (Ec032 and derivatives)
Experimental assays:
Biofilm biomass quantification, ERIC-PCR, Sanger sequencing
Content elements:
Figures S1–S2, Tables S1–S2
Strains described:
Ec032, Ec032Δ, Ec032ΔkduD, E. coli DH5α, E. coli WM3064
Plasmids described:
pCure-oriT-GFP-MCR, pCat-arr, pCasKp-OriT, pSGKp-arr2, pSGKp-Ec032-kduD, pSGKp-Ec032-kduD-500
Genetic elements:
kduD gene, sgRNA constructs, repair arms
Antibiotic resistance markers:
Apramycin, Rifampicin, Colistin
Techniques included:
Crystal violet staining, electrophoretogram analysis, primer design
Note:
Year
Theme:
Cell division, Mutant strains, Fluorescent proteins
Document Type:
Scientific Supplementary Information
Target Audience:
Researchers, Molecular Biologists
Year:
2022
Region / City:
Shivamogga, Karnataka, India
Theme:
Genetic variability, crop resistance, blackgram breeding
Document Type:
Research Paper
Organization:
Agricultural and Horticultural Research Station (AHRS), Bavikere
Author:
Not specified
Target Audience:
Researchers, agronomists, plant breeders
Period of Activity:
Kharif 2022, Summer 2023
Date of Approval:
Not specified
Date of Modifications:
Not specified
Year:
Not specified
Region / City:
Not specified
Topic:
Bacterial biology, Gram-negative bacteria, Lipopolysaccharides
Document Type:
Educational Material
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Students or professionals in microbiology
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Year
Year:
2026
Region / City:
London, United Kingdom; Urbana, Illinois, USA; New York City, USA; Glasgow, United Kingdom
Topic:
Breast cancer, ESR1 mutations, drug resistance
Document Type:
Research article
Institution:
The Institute of Cancer Research; University of Illinois at Urbana-Champaign; Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College; The Royal Marsden Hospital
Authors:
Belinda Kingston, Alex Pearson, Maria Teresa Herrera-Abreu, Li-Xuan Sim, Rosalind J Cutts, Heena Shah, Laura Moretti, Lucy S Kilburn, Hannah Johnson, Iain R Macpherson, Alistair Ring, Judith M Bliss, Yingwei Hou, Weiyi Toy, John A Katzenellenbogen, Sarat Chandarlapaty, Nicholas C Turner
Keywords:
Fulvestrant, acquired resistance, ESR1 F404, breast cancer, PIK3CA, TP53, ESR1 D538G, ESR1 E380Q, ESR1 Y537N
Methods:
Patient cohort analysis, progression-free survival assessment, CRISPR gene editing, RNA sequencing, clonogenic assays
Target Audience:
Oncologists, cancer researchers, molecular biologists
Supplementary Data:
Figures 1–9, mutation incidence, gene expression, drug response curves
Clinical Focus:
Acquired resistance to fulvestrant in ESR1 mutant breast cancer models
Year:
2021
Region / City:
Iraq
Topic:
Salt Tolerance, Potato Mutation Breeding
Document Type:
Research Article
Organization:
Scientific Research Commission, Baghdad, Iraq
Author:
AL-Hussaini Z.A., Abdulsada A.J., AL-Ani M.A.
Target Audience:
Researchers, Agronomists
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2019
Region / City:
United States
Topic:
Immigration Services
Document Type:
Instruction Manual
Organization:
U.S. Citizenship and Immigration Services (USCIS)
Author:
U.S. Citizenship and Immigration Services
Target Audience:
Individuals applying for immigration benefits
Effective Period:
Ongoing, with periodic updates
Approval Date:
10/15/2019
Date of Changes:
10/15/2019
Version:
1.01.00
Date:
12/14/2017
Originator:
K. Hutchinson
Description of Change:
Added T3 and T17 region fields, Deleted old region fields, Administrative changes
Scope:
One table for all FYs
Frequency of processing:
Provided from the POC only as changes are made to the list
Pharmacy ID (NCPDP) Format:
Char 7
Pharmacy Name Format:
Char 40
DMIS ID Format:
Char 4
Pharmacy NPI (formerly NPI Type 2) Format:
Char 10
Record layout and content:
All fields are variable length and delimited by “|”
Data Manipulation:
Using VLOOKUP, map NCPDP # to DMISID
Updates:
Updates to the table are no more than once a month
Note:
Data joins performed in M2
Region / city:
N/A
Type of document:
Specification document
Target audience:
Professionals involved in the MHS Mart system
Date of approval:
12/14/2017
Context:
Specification document for Pharmacy ID (NCPDP) Reference Table in MHS Mart (M2), detailing data formats, mappings, and updates procedures.
Year:
2024
Region / City:
United States
Topic:
Immigration
Document Type:
Instructional Manual
Agency:
U.S. Citizenship and Immigration Services (USCIS)
Author:
U.S. Citizenship and Immigration Services
Target Audience:
Individuals applying for Form I-192
Effective Period:
02/02/2024 - 02/28/2026
Approval Date:
02/02/2024
Date of Changes:
02/02/2024
Year:
2018
Region / City:
Long Beach, CA
Subject:
Commercial supplies and services for auditorium table repairs
Document Type:
Combined Synopsis/Solicitation
Agency / Organization:
Department of Veterans Affairs, Network Contracting Office 22
Author:
John Harrison, Contracting Specialist
Target Audience:
Service-disabled veteran-owned small businesses (SDVOSBs) and veteran-owned small businesses (VOSBs)
Period of validity:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Context:
Combined synopsis/solicitation notice for requesting quotes on auditorium table repairs for the VA Loma Linda Healthcare System.
Year:
2024
Region / City:
Not specified
Topic:
Postmortem MRI, Fetal MRI, Radiological Autopsy
Document Type:
Supplementary Material
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers, Medical Professionals
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
1991-2014
Region / City:
UK
Topic:
Labour Market Transitions, Demographic Analysis
Document Type:
Research Supplement
Author:
Not specified
Target Audience:
Researchers, Policy Analysts, Demographers
Period of Validity:
1991-2014
Approval Date:
Not specified
Date of Amendments:
Not specified
Year:
2025
Region / city:
EU
Topic:
Health Technology Assessment
Document Type:
Guidance
Organization / Institution:
HTA CG
Author:
European Commission
Target audience:
Professionals in Health Technology Assessment
Validity period:
From 28 NOVEMBER 2025
Approval date:
28 NOVEMBER 2025
Amendment date:
Not specified
Year:
2023
Region / City:
United States
Theme:
Immigration
Document Type:
Form
Institution:
U.S. Citizenship and Immigration Services (USCIS)
Author:
U.S. Citizenship and Immigration Services (USCIS)
Target Audience:
Applicants for refugee status and their legal representatives
Effective Period:
Until 08/31/2025
Approval Date:
08/10/2022
Modification Date:
10/17/2023
Year:
2026
Region / City:
Goa, India
Topic:
Data Collection & Consumption
Document Type:
Technical Report
Organization:
3GPP
Author:
Xiaonan Shi, Jean Trakinat
Target Audience:
3GPP members, 6G system developers
Period of Validity:
Ongoing
Approval Date:
TBD
Date of Modifications:
February 2026
Agenda Item:
x.x
Document for:
Approval
Contact:
Xiaonan Shi ([email protected]
Note:
)
Abstract:
Provides initial Table 14.1.5-3 for consolidation discussions on 6G data collection and consumption mechanisms.
Context:
This document is a technical report for discussion and approval of proposed requirements for data collection and consumption within 6G systems, focusing on privacy, security, and data processing.
Year:
2025
Region / City:
Eastern Atlantic and Mediterranean
Subject:
Bluefin tuna fishing and capacity management
Document type:
Template
Organization / Institution:
ICCAT Secretariat
Author:
ICCAT Secretariat
Target audience:
Panel 2 members, European Union, fishing industry stakeholders
Period of validity:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Contextual description:
Draft template for the capacity table related to bluefin tuna fishing, farming, and management plans, with a focus on quota adjustments and fleet capacity.
Note:
Study Summary 1.1 Please provide a brief summary of the study in the table below. A complete description of the study with detailed information should be provided in the body of the protocol. For sections not applicable to the study, mark them as N/A. Study Title Study Design Primary Objective/Purpose Secondary Objective(s)/Purposes Research Intervention(s) ClinicalTrials.gov NCT # Study Population Sample Size Study Duration for individual subjects Study Specific Abbreviations/ Definitions
Background 3.1 Provide the scientific or scholarly background for, rationale for, and significance of the research based on the existing literature and how will it add to existing knowledge. :
this section should be limited to only information directly related to the research questions and objectives. Do not include your full dissertation proposal. 3.2 Describe any relevant preliminary data (e.g. pilot data).
Procedures Involved 5.1 Describe and explain the study design. 5.2 Please select the methods that will be employed in this study (select all that apply):
☐ Audio/Video Recording ☐ Psychophysiological Recording ☐ Behavioral Interventions ☐ Record Review - Educational ☐ Behavioral Observations and Experimentations ☐ Record Review - Employee ☐ Deception ☐ Record Review- Medical ☐ Focus Groups ☐ Record Review - Other ☐ Interviews ☐ Specimen Collection or Analysis ☐ Investigational Medical Device – (e.g. Medical Mobile Applications) ☐ Surveys and/or Questionnaires ☐Psychometric Testing ☐ Other Social-Behavioral Procedures Provide a description of all research procedures being performed and when they are performed. (Upload any surveys, questionnaires, interview scripts, focus group scripts, debriefing scripts, psychometric tests, stimulus materials, intervention manuals, and data collection forms on the Local Site Documents page in the IRB application.) 5.3 Describe the procedures or interventions that are going to be conducted as part of the research project, but that would have been conducted anyway, even if the research was not occurring (i.e. standard of care procedures, activities that would occur in a classroom). 5.4 Describe the procedures performed to lessen the probability or magnitude of risks of items selected in 5.2.5. 5 If accessing or collecting existing data, describe: The data that will be collected during the study (e.g. demographics, medical history, etc.). Attach the data capture sheet(s) on the Local Site Documents page in the IRB application. How the data will be obtained, including how you have the authority to access the data. The source or location of the data (e.g. USF Epic, TGH Epic, Hillsborough County School records, CANVAS records, publicly available databases, etc.). 5.6 If collecting and/or analyzing biological specimens, describe: How the biological specimens will be or have been collected. How the biological specimens will be stored. How long the biological specimens will be stored. How the biological specimens will be used. The laboratories that will be used. Whether the collected biological specimens will undergo genetic testing. If so, indicate if this study is part of a Genome Wide Association Study (GWAS) and whether the data will be forwarded to the NIH dbGaP. 5.7 If there are plans for long-term follow-up (once all research related procedures are complete), what data will be collected during this period.
Data and Specimen Storage for Future Research 6.1 If data or specimens will be banked for future research studies, describe where the data or specimens will be stored, how long it/they will b:
the process to request a release, approvals required for release, who can obtain data or specimens, and the data to be provided with specimens.